0000000000144470

AUTHOR

Marco Maruzzo

0000-0002-6256-9249

showing 7 related works from this author

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC)

2014

e15568 Background: With the exception of the Temsirolimus (Tem) registration trial, prRCC pts are grossly underrepresented in trials that have evaluated different therapeutic strategies. Methods: W...

OncologyCancer Researchmedicine.medical_specialtyPoor riskbusiness.industrymedicine.diseaseTemsirolimusLarge cohortSurgeryOncologyRenal cell carcinomaInternal medicinemedicinebusinessmedicine.drug
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Second medical opinion in oncological setting

2021

Oncological patients increasingly require second medical opinions to feel more likely confident with their oncologists and treatments, although this could lead to wrong opinions and delay in the start of treatments. Second opinions can be required also by physicians to obtain advices, especially in case of rare tumors. The request of new opinions is documented in radiology and pathology settings too, with not negligible discrepancy rate. Conversely, the role in general medical/surgical conditions has not been well established. Literature is poor of studies relative to second opinions or they are more focused on patient's motivations. For these reasons, AIOM (Italian Association of Medical O…

0301 basic medicineDecalogueEthicsmedicine.medical_specialtyMeetingbusiness.industryFoundation (evidence)HematologyMedical Oncology03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyItalySecond medical opinions030220 oncology & carcinogenesisFamily medicinePhysiciansmedicinePosition paperHumansAIOM; Decalogue; Ethics; Meeting; Second medical opinions; Humans; Italy; Referral and Consultation; Medical Oncology; PhysiciansbusinessReferral and ConsultationAIOM
researchProduct

Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an explorato…

2016

Invasive breast cancer is the most common malignancy in women. Its most common site of metastasis is represented by the lymph nodes of axilla, and the sentinel lymph node (SLN) is the first station of nodal metastasis. Axillary SLN biopsy accurately predicts axillary lymph node status and has been accepted as standard of care for nodal staging in breast cancer. To date, the morphologic aspects of SLN metastasis have not been considered by the oncologic staging system. Extranodal extension (ENE) of nodal metastasis, defined as extension of neoplastic cells through the nodal capsule into the peri-nodal adipose tissue, has recently emerged as an important prognostic factor in several types of …

Breast cancer; ENE; Extra-nodal; Extracapsular; Extranodal; Sentinel; Oncology; Surgery0301 basic medicineOncologyBreast cancer; ENE; Extra-nodal; Extracapsular; Extranodal; SentinelMetastasis0302 clinical medicineBreast cancersentinelLymph nodeextracapsularmedicine.diagnostic_testExtracapsularextra-nodalGeneral MedicinePrognosismedicine.anatomical_structureOncologyLymphatic Metastasis030220 oncology & carcinogenesisExtranodalENEFemaleSentinel Lymph Nodemedicine.medical_specialtySentinel lymph nodeBreast NeoplasmsMalignancyDisease-Free Survival03 medical and health sciencesbreast cancerBreast cancerInternal medicineBiopsymedicineHumansSentinelSurvival analysisNeoplasm StagingSentinel Lymph Node Biopsybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryExtra-nodalAxilla030104 developmental biologyLymph Node ExcisionSurgerybusinessFollow-Up StudiesEuropean Journal of Surgical Oncology
researchProduct

INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

2021

BackgroundUntil now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs).MethodsThe prospective multicenter observational INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors (INVIDIa-2) study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving ICIs, enrolled in 82 Italian centers from October 2019 to January 2020. The primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020. Secondary endpoints regarded ILI severity and vaccine safety.ResultsThe study enrolle…

MaleCancer ResearchTime Factors2435immunogenicity0302 clinical medicineRisk FactorsNeoplasmsvaccineClinical endpointImmunology and Allergyantibodiesantibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine1506Prospective Studies030212 general & internal medicineImmune Checkpoint InhibitorsRC254-282Clinical/Translational Cancer ImmunotherapyAged 80 and overIncidenceIncidence (epidemiology)virus diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedVaccinationTreatment OutcomeItalyOncologyInfluenza Vaccines030220 oncology & carcinogenesisMolecular MedicineFemaleimmunotherapyAdultmedicine.medical_specialtyInfluenza vaccineImmunologyVaccine EfficacyimmunizationRisk AssessmentYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineHumansLung cancerAdverse effectAgedPharmacologybusiness.industryCancermedicine.diseasevaccinationImmunizationbusinessneoplasm
researchProduct

Supplementary_Material_-_online_only – Supplemental material for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhi…

2020

Supplemental material, Supplementary_Material_-_online_only for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG by Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casad…

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct